title: [125I]EGF binding in basal ganglia of patients with Parkinson's disease and progressive supranuclear palsy and in MPTP-treated monkeys.
abstract: Since EGF is known to protect and stimulate the activity of dopaminergic neurons, an autoradiographic study of [125I]EGF binding sites was performed in the striatum and pallidal complex in parkinsonian syndromes. The analysis was performed on postmortem brain tissues of three control subjects, three patients with Parkinson's disease, and three patients with progressive supranuclear palsy, another parkinsonian syndrome in which dopaminergic neurons also degenerate. Since all six patients had been treated with L-Dopa, we also analyzed the effects of this drug in an animal model of Parkinson's disease. Quantitative analysis of [125I]EGF binding was performed on the brains of three control monkeys, nine monkeys rendered parkinsonian by MPTP intoxication, three of which were treated with L-Dopa. An increased density of [125I]EGF binding was observed at anterior levels in the dorsal striatum, but not in the pallidum, of patients with Parkinson's disease and progressive supranuclear palsy. [125I]EGF binding was unchanged in parkinsonian monkeys whether or not they had been treated with L-Dopa. The data suggest an increased expression of EGFRs in the striatum in chronic parkinsonian syndromes but not in acute models of the disease.
authors.affiliation: INSERM U289, Hôpital de la Salpêtrière, Paris, France.
authors.forename: J
authors.initials: J
authors.lastname: Villares
authors.forename: B
authors.initials: B
authors.lastname: Faucheux
authors.forename: M T
authors.initials: MT
authors.lastname: Herrero
authors.forename: J A
authors.initials: JA
authors.lastname: Obeso
authors.forename: C
authors.initials: C
authors.lastname: Duyckaerts
authors.forename: J J
authors.initials: JJ
authors.lastname: Hauw
authors.forename: Y
authors.initials: Y
authors.lastname: Agid
authors.forename: E C
authors.initials: EC
authors.lastname: Hirsch
mesh_terms: D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D000368:Aged; D000369:Aged, 80 and over; D000818:Animals; D001479:Basal Ganglia / Q000378:metabolism*; D001927:Brain Diseases / Q000139:chemically induced / Q000378:metabolism; D015259:Dopamine Agents; D004815:Epidermal Growth Factor / Q000378:metabolism*; D066246:ErbB Receptors / Q000378:metabolism*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D007457:Iodine Radioisotopes; D008252:Macaca fascicularis; D008297:Male; D010300:Parkinson Disease / Q000378:metabolism*; D013494:Supranuclear Palsy, Progressive / Q000378:metabolism*; D013747:Tetrabenazine / Q000031:analogs & derivatives / Q000378:metabolism
chemical_list: D015259:Dopamine Agents; D007457:Iodine Radioisotopes; C032811:dihydrotetrabenazine; D004815:Epidermal Growth Factor; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D066246:ErbB Receptors; D013747:Tetrabenazine